MUMBAI -(Dow Jones)- India’s Suven Life Sciences Ltd. (530239.BY) Tuesday said it has signed an agreement with U.S-based pharmaceutical major Eli Lilly & Co. ( LLY) for preclinical research and development of molecules for central nervous system disorders.
